Medical Devices Pick Up After Three Years of Slow Performance; Learn Which Names in Ortho and Cardio Are Expected to Perform the Best

67 WALL STREET, New York - March 15, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

In the following excerpt from the Medical Devices Report, an expert analyst discusses the outlook for the sector for investors:

TWST: Are you finding those names in a certain subsector or are they all over the industry?

Ms. Wuensch: All over. The S&P 500 equipment and supplies index has outperformed the S&P 500 in the first two months of 2013. Some of the underperformers from last year have outperformed, but some of the more consistent, diversified names where we spend a lot of time have also done well. We've seen names move up nicely. Boston Scientific (BSX) has been the top performer in the space, on the heels of a depressed multiple. They are welcoming new management, and management has been talking more and more about the pipeline.

Some of the larger-cap orthopedic names such as Zimmer (ZMH) and Stryker (SYK) have also done well. And even the larger-cap cardiology names outside of Boston Scientific have had great starts for 2013. Medtronic (MDT) is up 10% year to date. The new Abbott (ABT) is up 7%. Covidien (COV) is up 10%. CareFusion (CFN) is up 15%. In general, the larger-cap names have outperformed the smaller-cap names as new money has come into the group.

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.